Table 2.
Molecular characterization of 19 PVL-positive Staphylococcus aureus clinical isolatesa
| Strain ID or phage (GenBank accession no.) | Date of isolationb (source) | ST (CC) | spa typec | Antibiogramd | Virulence profile | Nucleotide at gene position |
Sequence isoform | PVL phage typing PCR resulte |
PVL type | PVL isoform | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
lukS |
lukF |
||||||||||||||||||||||||||
| 33 | 105 | 181 | 216 | 345 | 470 | 527 | 663 | 1396 | 1729 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |||||||||
| TS13 | 17/03/09 (CA) | 22 (22) | t005 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | + | +* | ΦPVL | H1 | |||||
| TS14 | 04/03/09 (HA) | 22 (22) | t005 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS18 | 11/11/08 (CA) | 22 (22) | t005 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS20 | 03/02/09 (CA) | 22 (22) | t005 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS24 | 06/11/08 (CA) | 22 (22) | t005 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS19 | 30/12/08 (CA) | 22 (22) | t310 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS17 | 04/12/08 (CA) | 22 (22) | t852 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS6 | 06/05/09 (HA) | 22 (22) | t6642 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS9 | 07/04/09 (HA) | 22 (22) | t6642 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS23 | 16/12/08 (CA) | 22 (22) | t6643 | Gent, Trim R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS1 | 18/03/09 (CA) | 1518 (152) | t1941 | Fully sens | None | G | T | T | C | C | T | G | T | A | G | R | + | + | +* | + | ΦSa2USA | R | |||||
| TS5 | 23/04/09 (CA) | 772 (1) | t657 | Trim, Cipro, Ery R | sea, sec, seg, sei | G | T | T | C | C | T | A | G | A | A | H2 | |||||||||||
| TS8 | 08/04/09 (CA) | 772 (1) | t345 | Trim, Cipro, Ery R | sea, sec, seg, sei | G | T | T | C | C | T | A | G | A | A | H2 | |||||||||||
| TS25 | 05/12/08 (CA) | 1 (1) | t3342 | Trim R | sed, seg, sei | A | T | T | C | T | T | A | G | A | A | H2 | + | + | +* | + | ΦPVL/ΦSa2mw | H1/R | |||||
| TS7 | 04/04/09 (CA) | 30 (30) | t021 | Trim, Doxy R | sea, seg, sei | G | T | T | C | C | A | A | G | A | A | H2 | + | + | +* | ΦPVL | H1 | ||||||
| TS12 | 18/03/09 (CA) | 30 (30) | t021 | Gent, Trim, Cipro, Ery R | seg, sei | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | ΦPVL | H1 | ||||||
| TS15 | 12/02/09 (CA) | 30 (30) | t021 | Fully sens | seg, sei | G | T | T | C | C | A | A | G | A | A | H2 | + | + | +** | Φ108PVL | H2 | ||||||
| TS16 | 11/02/09 (CA) | 30 (30) | t021 | Trim R | sea, seg, sei | G | T | T | C | C | A | A | G | A | A | H2 | + | + | +* | ΦPVL | H1 | ||||||
| TS21 | 11/02/09 (HA) | 88 (88) | t6769 | Trim R | None | G | T | T | C | C | T | A | G | G | A | H1 | + | + | +* | Elongated head | |||||||
| ΦSLT (NC_002661) | G | T | T | C | C | T | A | G | A | A | + | + | + | ΦSLT | H2 | ||||||||||||
| Φ108PVL (AB243556.1) | G | T | T | C | C | T | A | G | A | A | + | + | +** | Φ108PVL | H2 | ||||||||||||
| ΦPVL (AB009866.2) | G | T | T | T | C | T | A | G | G | A | + | + | +* | ΦPVL | H1 | ||||||||||||
| Φ2958PVL (AP009363.1) | G | T | T | C | C | T | A | G | G | A | + | + | + | Φ2958PVL | H1 | ||||||||||||
| ΦSa2mw (BA000033) | G | T | T | C | C | T | G | T | A | A | + | + | + | ΦSa2mw | R | ||||||||||||
| ΦSa2USA (CP000730.1) | G | T | T | C | C | T | G | T | A | G | + | + | + | ΦSa2USA | R | ||||||||||||
a
Total toxin genes analyzed include sea, seb, sec, sed, see, seg, seh, sei, sej, tst, eta, etb, and etd. ID, identifier; HA (hospital associated), isolated after 48 h of admission; CA, isolated either at the general practice or accident and emergency department or within 48 h of admission.
b
Day/mo/yr.
c
The spa types underlined were described for the first time in this study.
d
R, resistant; Gent, gentamicin; trim, trimethoprim; Cipro, ciprofloxacin; Ery, erythromycin; Doxy, doxycycline; sens, sensitive.
e
“*” and “**” indicate 1,411 bp and 4,340 bp, respectively.